Rezolute, Inc. (RZLT) can sell. Click on Rating Page for detail.
The price of Rezolute, Inc. (RZLT) is 3.95 and it was updated on 2024-06-16 07:00:51.
Currently Rezolute, Inc. (RZLT) is in undervalued.
News |
---|
Rezolute to Participate in the Jefferies Global Healthcare Conference
|
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
|
$DED: What Do We Know So Far?
|
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
|
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
|
StockPrice Release |
---|
Rezolute added to russell microcap® index
|
Rezolute announces change of transfer agent
|
News |
---|
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
|
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
|
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
|
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
|
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
|
Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism
|
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
|
Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"
|
Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day
|
Rezolute Reports First Quarter Fiscal 2024 Results
|
Rezolute: Negative EV Opportunity Initiating A Phase 3 Ultra-Orphan Pediatric Study
|
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
|
Rezolute Announces Further Evidence of RZ358's Efficacy in Tumor-Mediated Hyperinsulinism
|
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
|
Rezolute to Participate in Upcoming Investor Conferences in September
|
Rezolute to Present at the Jefferies London Healthcare Conference
|
Rezolute, Inc. (RZLT) Upgraded to Buy: Here's Why
|
Rezolute (RZLT) Posts Positive Data From Congenital HI Study
|
Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering
|
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering
|
Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021
|
Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress
|
Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism
|
Rezolute to Participate in Upcoming Virtual Healthcare Conferences
|
Rezolute Added to Russell Microcap® Index
|
5 Stock Gainers For May 27: VTNR, GOED, RZLT, AMC, RVPH
|
RZLT Stock Price: Over 85% Increase Explanation
|
Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs
|
Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit
|
Rezolute to Participate in Upcoming Investor Conferences in March
|
Rezolute Reports Second Quarter Fiscal 2021 Financial Results
|
Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
|